IDEAYA Biosciences, Inc. (IDYA): Revenue
$218.71M
Year ended 2025-12-31
+62.5%
3-year compound annual growth
+62.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $218.71M | n/m | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $7.00M | -70.1% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $23.39M | -54.1% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $50.93M | +82.3% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $27.94M | +43.0% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $19.54M | n/a | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $0 | n/a | 2022-03-18, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $218.71M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $216.10M | +8.7% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $213.65M | -6.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $228.37M | -0.9% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $234.60M | +157.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $236.20M | +47.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $244.06M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $247.00M | -4.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $189.76M | +45.8% |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗